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ABSTRACT OF THESIS 
CHARACTERIZATION AND EVALUATION OF 
 ANDROGEN-BINDING PROTEIN, SEX HORMONE-BINDING GLOBULIN, 
AND THYROXINE-BINDING GLOBULIN  
IN THE HORSE  
The objectives of this study are to characterize two carrier proteins in the horse 
that significantly decrease in humans following anabolic androgenic steroid 
administration: sex hormone-binding globulin (SHBG) and thyroxine-binding globulin 
(TBG). For SHBG characterization, qPCR, RNA sequencing, and immunohistochemistry 
were performed on testes and equine livers. Free and total testosterone immunoassays 
were utilized to confirm the presence of a carrier protein in equine circulation. SHBG 
was detected in the testes using qPCR, RNA sequencing, and IHC, indicating the 
presence of the isoform androgen-binding protein (ABP). SHBG was not detected in any 
liver samples. Evidence of a carrier protein was shown by free testosterone being 
significantly lower than the total testosterone that was detected in stallions (p<0.0001) 
and pregnant mares (p<0.0001). TBG characterization was completed using an equine 
specific TBG ELISA. Equine serum was analyzed across seasons, reproductive statuses, 
sexes, and ages. TBG concentrations were also measured following anabolic steroid 
administration (Stanozolol) and increased endogenous androgen production via hCG 
administration in stallions and aromatase inhibition via Letrozole administration in 
pregnant mares. TBG did not significantly differ across season, reproductive status, sex, 
or age Alterations of androgen concentrations did not result in any significant changes to 
circulating TBG concentrations.  
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Chapter One: Introduction and Objectives 
Equine athletics form a multi-faceted industry that is represented all over the 
world. Just like human athletics, fairness between competitors needs to be ensured. This 
is done by testing the athletes for performance-enhancing substances that could provide 
them with an advantage over other competitors [1]. The abuse of these substances with 
the specific intent to enhance performance is referred to as “doping”.   
The current testing methods that are available have advantages and disadvantages, 
but all have the same goal – the detection of the specific substance that was administered. 
While this is acceptable for the published list of banned substances, it leaves room for the 
use of novel or “designer” steroids, which can go undetected [2].  In human sports, a new 
means for identifying cases of doping was proposed in 2000 and is called “The Athlete 
Biological Passport” [3].  
The Athlete Biological Passport monitors changes within certain parameters in the 
body that are caused by the administration of some foreign substance [3]. These 
parameters are called biomarkers and are indirect indicators of substance administration. 
The biomarkers of interest for the purpose of this investigation are carrier proteins that 
can be measured in serum or plasma, specifically sex hormone-binding globulin (SHBG) 
and thyroxine-binding globulin (TBG). While these biomarkers have been verified and 
characterized in humans, there is little to no literature regarding them in the horse.  
The objectives for the current study are; 1) to find and characterize SHBG in 
circulation and tissues in the horse and 2) to characterize circulating levels of TBG across 
varying reproductive statuses, seasonal changes and with increased androgen levels.   
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Chapter Two: Review of the literature 
Anabolic Steroids 
In many human and equine sports, it is not uncommon for competitors to use 
various agents in order to gain an advantage over their opponents.  The illegal use of 
these agents is referred to as “doping”. While there are many different categories of 
doping substances, the most commonly used are anabolic agents or anabolic androgenic 
steroids (AAS) [4].  AAS are structurally similar to   testosterone and contain various 
modifications to improve their effects.  Although they originate from androgens, the 
anabolic effects are the focus of these drugs.  They cause an increase in muscle 
development, the production of red blood cells, and synthesis of proteins [5].   However, 
the use of AAS is prohibited in athletic competition when administered in levels much 
higher than therapeutically prescribed [4].  The guidelines for illegal substances and their 
use in human athletes are established by the World Anti-Doping Agency (WADA) [5].  
Currently, testing for such substances requires direct identification through the use of 
liquid or gas chromatography in conjunction with mass spectrometry [6]. While this is 
considered a state of the art approach, it cannot identify AAS that are unknown, causing 
certain products and metabolites to go undetected.  The pharmaceutical industry 
continues to produce new drugs faster than anti-doping researchers can detect them.   
As previously mentioned, anabolic steroids are primarily derived from 
testosterone with various modifications. These modifications are necessary to ensure that 
the substance will not be metabolized or absorbed before being able to generate it’s 
intended effects [5]. These modifications are classified into three different types based on 
the desired route of administration. A type A change results from the esterification of the 
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17ß-hydroxyl group and makes the compound better suited for injection. A type B 
modification is caused by the addition of an alkyl group to the 17α-position and makes 
the molecule active when administered orally. A type C change is the result of modifying 
the ring structure of testosterone and increases its potency while slowing its metabolism 
when taken orally. Most anabolic steroids contain a combination of either a type A or B 
modification in addition to a type C [5, 7]. 
 
Figure 2.1: Types of testosterone modifications for anabolic use [5] 
 When testosterone concentrations are that of normal circulating levels, it is 
reported that the receptors that respond to testosterone and 5α-dihydrotestosterone (DHT) 
are fully saturated. This gives rise to a theory that anabolic steroids may be acting 
through another receptor, the glucocorticoid receptor [8]. Corticosterone and cortisol are 
glucocorticoids (GCs) and when bound to their receptor influence protein breakdown. It 
is postulated that the “supraphysiological” concentrations of androgens following 
anabolic administration results in the displacement of GCs from their receptor [9], 
preventing muscle protein catabolism and resulting in muscle production [8]. 
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 In the early 2000’s a new approach to detecting the administration of banned 
substances was proposed. This was called the “Athlete Biological Passport” [3]. The 
Athlete Biological Passport suggests monitoring various biomarkers in order to detect the 
administration of an outside substance. A biomarker is defined as “any measurable 
parameter altered as a result of a challenge to an individual’s system” [10]. Currently, the 
idea of an Equine Biological Passport is being brought to light [11]. While this would be 
able to test for a much wider range of substance administration, biomarkers in horses 
have yet to be as extensively established as in humans. In humans, there are two carrier 
proteins that react similarly to the administration of AAS, SHBG and TBG.  
 A study conducted by Ruokonen et. al, measured SHBG concentrations in men 
who self-administered AAS [12]. This study showed that within 8 weeks of beginning 
AAS administration, SHBG levels dropped 80-90% compared to the control athletes. 
These levels remained low and had still not returned to normal circulating levels at the 
conclusion of the study, which was after a 16-week administration withdrawal period. 
Not only did this study show the significant decrease in SHBG due to AAS 
administration, but it also indicated that this significant difference was detectable 12 
weeks after the administration ceased. This is ideal in a biomarker because it prevents the 
athlete from being able to train under the influence of AAS and bypass detection by 
ceasing drug administration shortly before competition.  
 In cattle, it has also been shown that SHBG could be used to detect the use of 
growth promoters. Mooney et. al used immobilized 1alpha-dihydrotestosterone (DHT) to 
detect SHBG binding capacity as an indirect indicator of SHBG concentrations [13]. 
SHBG has the highest affinity for DHT out of the steroid hormones present in circulation 
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[14]. Both treated male and female cattle showed significantly lower SHBG binding 
capacities when compared to their respective control group.  
 Just as self-administration of AAS in men has shown a reduction in circulating 
SHBG, it has also shown a significant decrease in TBG levels. Alén et. al, measure both 
TBG and SHBG concentrations in athletes following AAS administration [15]. Within 4 
weeks of beginning administration, TBG and SHBG levels dropped significantly in the 
treated athletes. These concentrations remained low throughout the administration period, 
as well as during the monitored 12-week withdrawal period. The fact that TBG also 
remained low for several weeks without the administration of AAS makes it an ideal 
biomarker. The mechanisms as to how these protein concentrations are affected by 
exogenous steroid administration will be discussed in the following sections.  
Sex Hormone-Binding Globulin 
SHBG is a glycoprotein found in circulation of all vertebrate classes, except for 
birds [16].  Sex hormones bind to SHBG and it regulates their bioavailability [17]. In 
most vertebrates, androgens  and estrogens circulate in three forms: bound to albumin, 
bound to SHBG, and unbound/free [18]. While albumin binds to sex steroids, it also 
binds to all classes of steroids with low affinity and without any real specificity [19]. In 
doing so, albumin can increase the half-life of these hormones, but they can easily 
dissociate from the protein [20]. Steroids that are bound to albumin or free in circulation 
are considered to be bioavailable due to their ability to readily act on target tissues [21]. 
SHBG on the other hand, solely binds to sex hormones with a much higher affinity and is 
therefore considered the main regulator of their bioavailability, as well as their primary 
transporter [22]. SHBG can then ensure that there is a readily available pool of sex 
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hormones where and when they are needed [23]. In most species, SHBG has a higher 
affinity for androgens, however, salmon SHBG has a higher affinity for estrogens [22].  
In addition to regulating the amount of sex hormone that can be used by tissues, 
SHBG has been shown to interact with membrane receptors as part of a steroid signaling 
pathway [24]. This has been well characterized in tissue explants and cultured cells from 
the breast and prostate of humans [25]. SHBG assists steroids in intracellular signaling 
via a G-protein without the steroids having to enter the cell [26]. When SHBG binds to 
the specific membrane receptor, a complex is formed, RSHBG [27]. SHBG can only bind 
to the membrane receptor when it is unbound, meaning that it does not have a sex 
hormone currently bound to it [26]. The RSHBG complex is then activated when the needed 
estrogen or androgen binds to it, independent of estrogen or androgen receptor binding 
[27] . This activation causes an increase in 3',5'-cyclic adenosine monophosphate (cAMP) 
[28, 29], leading to many potential downstream effects. These effects have included 
decreased progesterone receptor expression [30], increased prostate specific antigen 
expression [31], protein kinase A activation [32], and induced apoptosis [33].  
SHBG is primarily produced in the liver [34]. This is the form that is found in 
circulation bound to sex steroids. The Shbg gene is also expressed in the testes where the 
well-known isoform of SHBG, ABP, is transcribed [34]. The Shbg gene is also expressed 
in a few other tissues that are hormonally reactive. In humans, this gene is also expressed 
in the brain, prostate, breast, and endometrium [35, 36]. The transcript for ABP is present 
in the brain of rats, however it does not seem to have any steroid-binding activity [37]. 
The rat brain also contains the form of SHBG found in the fetal liver, although it contains 
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a different N-terminal sequence that prevents this protein from being secreted or binding 
to steroids [38].  
The rat and mouse Shbg loci were found on chromosomes 10 and 11 [39, 40]. In 
humans, chromosome 17 is homologous to chromosome 11 in mice, making it the 
location of the Shbg gene [41]. The form of SHBG that is produced in the human liver is 
considered to be the major transcript from the Shbg locus. This transcript is 4.3-kb and 
eight exons long with the first exon containing the secretion signal peptide [22]. The 
product of this transcription is a precursor protein containing 402 amino acids [17]. This 
product is then cleaved at the amino-terminus, removing a 29 amino acid long peptide 
[42-44], which results in the mature protein which contains 373 amino acids. This protein 
is then glycosylated with one O-linked oligosaccharide moiety and two N-linked 
oligosaccharide chains that are biantennary [45]. While the human Shbg gene contains 
eight exons, the number of exons in this gene can be variable between species. The 
bovine gene, for instance, contains twelve exons [46] while the gene in rats contains eight 
exons similar to the human gene [40]. 
The regulation of SHBG transcription and secretion has been a question for many 
years. It has been shown that in castrated monkeys, the administration of testosterone 
decreases circulating levels of SHBG, but the mRNA levels increased [47]. The direct 
effect of androgens on hepatic production of SHBG has never been demonstrated, 
indicating that the decrease in circulating concentrations of the protein is due to 
posttranscriptional modifications [22]. The mechanism as to how estrogens regulate 
SHBG production is more thoroughly described. The activation of estrogen receptors, 
ERα and ERβ, causes the downregulation of peroxisome proliferator-activated receptor 
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gamma (PPARγ) [48]. PPARγ has been shown to downregulate the expression of SHBG 
[49]. With estrogen receptor activation decreasing the amount of PPARγ, the 
concentration of SHBG is able to increase. The exact mechanism for the effects of 
androgens on SHBG concentrations has yet to be described.  
Androgen-Binding Protein 
Structural and immunochemical studies involving rabbit and human ABP and 
SHBG found that the two proteins are almost indistinguishable when amino acid 
sequences are compared [34, 50-52]. While SHBG and ABP are both transcribed from 
the same gene (Shbg), the proteins themselves are different due to their glycosylation [42, 
53]. Rabbit and rat ABP have been shown to contain the same N-linked oligosaccharide 
chains as human SHBG, but it is unclear if rat ABP also contains the O-linked chain [34].  
 ABP is transcribed from the Shbg gene and produced in Sertoli cells in the testis 
following  stimulation from FSH [54]. Unlike SHBG, ABP is not secreted into systemic 
circulation in humans [55]. The transcript for human ABP lacks the secretion signal 
peptide by having an alternative coding exon 1 [22]. ABP remains in the testes to ensure 
a readily available pool of testosterone needed for spermatogenesis [55]. Roughly 20% of 
ABP produced is secreted into the interstitial spaces, while 80% remains in the 
seminiferous tubules [56]. On the other hand, ABP in male rats is secreted into 
circulation from 20 to 40 days of age [57]. It is assumed that rat ABP in circulation has 
the same function as liver secreted SHBG, however this has not been investigated.  
 In the testes, ABP transports testosterone in seminiferous tubule fluid to the 
epididymis [56]. There ABP either dissociates and is taken up by the epididymal 
epithelium, or it progresses through the epididymis and is excreted in the seminal plasma 
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[16, 56]. ABP has been identified in the seminal plasma of caprine, bovine, and ovine, 
but has not been detected in that of humans, porcine, or equine [58]. In addition to 
providing a pool of testosterone for spermatogenesis, it has been reported that ABP helps 
maintain spermatozoal fertilizing capabilities [59]. Hypophysectomized rats experienced 
decreased circulating levels of testosterone. Following pregnenolone injections, 
testosterone levels in circulation remained low, however testosterone levels in the rete 
testis were normal. Sperm fertilizing capabilities and ABP concentrations were measured 
in these rats. A positive correlation was seen between ABP concentrations in the 
epididymis and sperm fertilizing capabilities [59]. 
Thyroxine-Binding Globulin 
 Thyroxine-binding globulin is another glycoprotein that can be found in 
circulation in most large herbivorous and omnivorous mammals [60, 61]. Carnivores are 
able to obtain a sufficient amount of thyroid hormones from their prey while omni- and 
herbivores rely on the storage of large amounts of thyroid hormones to make up for 
potential low iodine supply [61].  TBG binds to and regulates the bioavailability of 
thyroxine (T4) and triiodothyronine (T3) [62]. Thyroid hormones circulate bound to 
albumin, TBG, transthyretin or free and unbound [62]. Like sex hormones, the free 
thyroid hormones are considered to be biologically active. Due to the lower binding 
affinity, thyroid hormones bound to albumin are considered to be bioavailable as well. 
However, only 0.3% of T3 and 0.03% of T4 circulate unbound [60]. The affinity for 
thyroid hormones to TBG is 50 to 7000 times higher than their affinity for transthyretin 
or albumin, making TBG the primary regulatory of thyroid hormone bioavailability  [60]. 
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TBG is able to ensure that a readily available pool of thyroid hormones is present when 
needed by target tissues [62].  
A study conducted by Mendel et al. in 1987 showed that in addition to providing 
storage of thyroid hormones, TBG also assists in ensuring even distribution of thyroid 
hormones [63]. They examined the distribution of T4 within hepatic lobules in the rat in 
the presence of TBG and transthyretin and solely in the presence of albumin. In the 
absence of the thyroid hormone-binding proteins, T4 was taken up primarily by the 
peripheral cells within the lobule. However, when TBG and transthyretin were present, 
T4 was taken up by all cells in a uniform manner [63].  
 TBG is a 54-kDa single polypeptide chain that is transcribed in the liver from the 
serine protease inhibitor superfamily (SERPINA7), which is located on the long arm of 
the X-chromosome[64]. The gene contains 5 exons, only four of which are encoding [64]. 
The pre-protein contains 415 amino acids and is considered to be an acidic glycoprotein 
[60]. The mature molecule is a 395-amino acid protein that contains four N-linked 
oligosaccharides that assist in post translational folding [60]. The gene also contains 
multiple hepatic nuclear factor binding sites which further convey that transcriptional 
regulation is liver specific [64].  
 A study conducted by Larsson et al. in 1985 investigated the presence of TBG in 
15 vertebrate species [65]. Of the 15 species investigated, they were able to detect the 
presence of TBG in 9 of them by way of T4 affinity chromatography, electrophoresis, 
and autoradiography. The full list of animals tested as well as the properties of TBG that 
were investigated are listed in Table 1.1. 
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Table 2.1: List of animals investigated for the presence of TBG, as well as 
investigated properties of the protein [65]. 
 
 While TBG has been verified in quite a few species, including the horse [65], it 
has only been structurally characterized in rats, sheep, cattle, pigs, and humans [61]. 
Bovine TBG shows that 85.5% of its nucleotides are identical to that of human TBG and 
82.8% of the amino acids are identical [61]. Sheep share 80% homology with the amino 
acid sequence of human TBG and 85% homology with its nucleotides [66]. Like bovine 
and ovine TBG, porcine TBG also shows greater than 80% homology with human TBG 
in its amino acid (82.6%) and nucleotide (85.7%) sequences [61]. This high degree of 
interspecies sequence retention is an indication of the important role that TBG plays.  
 Circulating levels of TBG are affected by changes in steroid hormone 
concentrations by way of post-translational modifications. It has been shown that the 
administration of exogenous estrogens increases the sialic acid content of TBG which 
reduces its clearance rate in the liver, therefore increasing the circulating concentrations 
of TBG [67]. Currently, there are no studies that have specifically investigated the 
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mechanism in which exogenous androgens decrease TBG concentrations. However, it is 
postulated that androgens would decrease the sialic acid content of TBG, resulting in an 
increased clearance rate in the liver and decreasing TBG concentrations in circulation 
[68].   
 The following investigation was conducted with the objectives of characterizing 
SHBG and TBG in the horse. For SHBG, analysis of tissue expression was completed as 
well as examining the existence of a carrier protein in circulation. Since TBG has already 
been verified in the horse [65], the characterization of this protein was a little bit more in 
depth. TBG concentrations were investigated in regard to varying reproductive statuses, 
sexes, ages, and increased androgen concentrations. By characterizing SHBG and TBG, 
they could potentially be used as biomarkers in equine athletics. 
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Chapter 3: Characterization of androgen-binding protein and sex hormone-binding 
globulin in the horse 
B.O. Fleming, A. Esteller-Vico, S.E. Loux, K.E. Scoggin, B.A. Ball 
Note 
 The original objective of this study was to identify and characterize SHBG in the 
horse for the potential use as a biomarker for AAS abuse. The results obtained showed 
that SHBG was not present in circulation in the horse. However, through the process of 
searching for SHBG, the isoform ABP was verified in equine testes. Therefore, the 
following chapter will focus on ABP expression in the horse and evidence for an 
alternative carrier protein for androgens in circulation as opposed to specific SHBG 
characterization in the horse. 
Abstract 
The regulation of androgen bioavailability is an area that has not been well 
described or investigated in the horse. In most vertebrate species, androgen-binding 
protein (ABP) is the primary androgen regulator in the testes and sex hormone-binding 
globulin (SHBG) is the primary regulator in circulation. ABP and SHBG have yet to be 
identified in the horse. The objectives of this study were to 1) characterize the expression 
of ABP/SHBG in stallion testis, pregnant mare, fetal, and stallion liver through the use of 
qPCR and RNA sequencing, 2) visualize immunolocalization of ABP/SHBG in pre-, 
peri-, and post-pubertal equine testes and mare liver with immunohistochemistry, 3) 
provide evidence of a carrier protein in circulation by comparing free and bound 
testosterone concentrations in pregnant mares and human chorionic gonadotropin (hCG) -
stimulated stallions with free testosterone and total testosterone immunoassays, as well as 
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to investigate the presence of SHBG in circulation using heterologous immunoassays. 
RNA was isolated from liver [mare (n=1), fetus (n=1), stallion (n=1)], and testis (n=3). 
This RNA was then sequenced at the University of Illinois. For qPCR, RNA was isolated 
from testis (n=7) and equine liver [mare (n=3), fetal (n=2), stallion (n=2)] and reverse 
transcribed. Primers for SHBG (XM_001918151.3) were generated using NCBI and 
qPCR was performed. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and beta-2 
microglobulin (B2M) were used as reference genes. RNA sequencing showed a five-exon 
transcript (Chr 11: 50589067..50591923) in stallion testis, which would be ABP. ABP 
was amplified in the testis using qPCR ∆Ct = 4.179 ± 0.591 (mean ± SEM) and shown to 
be approximately 4000x greater than any amplification seen in the liver samples (16.480 
± 0.632). Immunolocalized ABP was seen in the seminiferous tubules and the interstitial 
spaces of the testis with IHC. No positive staining for SHBG/ABP was seen in the liver. 
Both the hCG-stimulated stallions and pregnant mares had significantly less free 
testosterone than total testosterone as determined by immunoassay. This provides 
evidence of a carrier protein in circulation in the horse. SHBG fell below the level of 
detection of the heterologous SHBG assays that were utilized. Although ABP is present 
in the equine testis, these results do not support the presence of SHBG in blood and 
suggest that there is a carrier protein for androgens in circulation in the horse other than 
SHBG. 
Introduction 
 The regulation of bioactive androgens in vertebrates is important due to the 
physiological roles that they play [21]. In males, testosterone is necessary for 
spermatogenesis and the development of secondary sex characteristics [21, 69]. 
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Compared to males, the function of androgens is not as well characterized in females, 
however they seem to be primarily used as precursors for estrogen synthesis throughout 
the body and within the ovary [70]. Low testosterone levels in men have been associated 
with poor sperm parameters and poor cardiovascular health [71]. In women, androgen 
dysregulation can result in polycystic ovarian syndrome [72], which can lead to 
metabolic as well as reproductive issues [73]. In order to control the effects of androgens 
within the body, bioavailable androgen levels are regulated by androgen binding protein 
(ABP) and sex hormone-binding globulin (SHBG) in many species [22, 55]. 
ABP is a carrier protein that is produced and secreted by Sertoli cells [54] and has 
been identified in the human, dog, monkey, rat, rabbit, ram, bull, and goat [16]. It is not 
secreted into systemic circulation and remains in the testes to ensure that there is a readily 
available pool of testosterone for spermatogenesis [55]. One third of androgens in 
testicular blood circulate bound to ABP, while the remaining fraction is free and unbound 
[74]. This protein transports testosterone via the seminiferous tubule fluid into the 
epididymis, where it dissociates and is taken up by epithelial cells [56]. In addition to 
supporting spermatogenesis, it is reported that ABP might help in maintaining the 
fertilization ability of spermatozoa in the epididymis [59]. In a study conducted using 
hypophysectomized rats that received pregnenolone injections, the rats had low 
circulating levels of testosterone, but normal testosterone levels in the rete testis. Sperm 
fertilizing capabilities were also measured and there was a positive correlation seen 
between sperm fertilizing capabilities and ABP concentrations in the luminal 
compartments and epididymis [59].  In some species, ABP is not taken up but will be 
excreted in the seminal plasma instead [16]. ABP has been identified in the seminal 
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plasma of caprine, bovine, and ovine, but is not present in that of humans, porcine, or 
equine [58]. While the absence of ABP in equine seminal plasma has been reported, its 
presence in stallion testes has yet to be investigated.  
In many vertebrates, ABP is an isoform of a protein that can be found in 
circulation to provide a readily available pool of sex hormones. This protein is call sex 
hormone-binding globulin (SHBG) [17]. Testosterone circulates in three known forms; 
free and unbound, bound to albumin, or bound to SHBG [21]. In order for testosterone to 
be able to act on its target tissues it must be considered “bioavailable”, which is 
testosterone that is either bound to albumin or free and unbound in circulation [18]. 
SHBG binds to androgens with high affinity making it difficult for them to dissociate 
until needed [23]. The affinity between androgens and albumin is weaker than that of 
SHBG, which allows the hormone to easily dissociate from albumin and join the free 
fraction to be used by its target [20]. Because testosterone cannot dissociate as easily 
from SHBG, this causes SHBG to be the primary regulator of bioavailability in the 
species where SHBG is present [22].  
Unlike ABP, SHBG is present in both males and females. In women, 
concentrations of SHBG are approximately 50% higher than in men, which results in less 
bioavailable testosterone [21, 22]. Also, the concentration of SHBG increases during 
pregnancy in women and other mammals including mice, rabbits, and rats [75, 76]. This 
coincides with the peak of testosterone that occurs during pregnancy [40, 77]. This 
increase in SHBG in maternal circulation is due to its production from the fetal liver in 
order to decrease the bioavailability of circulating testosterone [77]. This reduction in 
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bioavailability of androgens is proposed to both protect the dam from androgens 
produced by the fetus and protect the fetus from exposure to sex steroids [77]. 
While the function of SHBG is known and well described, it’s expression is 
variable between species. In humans, cattle, sheep, dogs, nonhuman primates, and many 
more species, SHBG has been identified in the liver and in circulation [13, 16, 78, 79]. In 
rats, SHBG is expressed in the liver of neonates, but within weeks of birth the expression 
declines and ceases in adulthood [80]. Salmon have a unique SHBG related gene that is 
found in their muscle, ovary and gill, but is not expressed in their liver or testes [22]. In 
elephants, camels, donkeys, and pigs there is no transcript for SHBG found in the liver, 
indicating that it is not used as the primary carrier for androgens in circulation for these 
animals [81-83]. While there is a gene for SHBG found in the equine genome [84], there 
are contradictory reports that it is not found in circulation in horses [82, 84, 85]. By way 
of radioactive steroid labelling in conjunction with ammonium sulfate precipitation 
followed by electrophoresis, it was concluded that SHBG was not present in the horse 
[82, 85]. However, Wenn et. al discusses concerns about radiolabeled steroid dissociation 
during the electrophoretic procedure, which has led to the claim that SHBG was not 
present in other species before [82].  
Though ABP and SHBG have been verified and somewhat described in many 
mammals [22], the horse is not one of them. Therefore, the objectives of this study were 
to; 1) characterize the expression of ABP/SHBG in stallions testi, pregnant mare, fetal, 
and stallion liver through the use of qPCR and RNA sequencing, 2) visualize 
immunolocalization of ABP/SHBG in pre-, peri-, and post-pubertal equine testes and 
mare liver with immunohistochemistry, 3) provide evidence of a carrier protein in 
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circulation by comparing free and bound testosterone concentrations in circulation of 
pregnant mares and hCG-stimulated stallions with free testosterone and total testosterone 
immunoassays, as well as investigate the presence of SHBG in circulation using 
heterologous immunoassays.   
Materials and Methods 
Animal Use and Tissue Collection:   
Experiments 1 & 2: 
Testes were collected post mortem from seven stallions (>3 years) and by way of 
castration from four peri-pubertal (2 years) and six pre-pubertal (>1 year) colts. Livers 
were collected post mortem from two fetuses (10 months gestation), three pregnant mares 
(>3 years) and three stallions. Post mortem tissues were fixed in neutral buffered formalin 
for IHC or RNA later for qPCR and RNA sequencing, while tissues collected via 
castration were fixed in formalin then transferred to methanol for IHC.  
Experiment 3: 
 
 Blood was collected from pregnant mares (n=18) via jugular venipuncture using 
blood tubes containing no anticoagulant (Butler Animal Health Supply, Dublin, OH). 
Stallions (n=4) received intravenous injections of 5000 international units of hCG as per 
standard protocol (University of Kentucky IACUC 2013-1088). Blood was collected 
from the treated stallions as well as control stallions (n=4) prior to injection as well as 1, 
2, 6, 12, 24, 48, 72, 96 hours, and 10 days post hCG.  Blood was then spun down at room 
temperature at 1,200 RCF rpm for 20 minutes until separated. Serum was then collected, 
aliquoted and stored at -20°C until analysis. 
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qPCR: 
Tissue samples stored in RNAlater were weighed out to 75 mg to be used for total 
RNA extraction by means of Trizol reagent following manufacturer’s instructions 
(Invitrogen, Carlsbad, CA, USA). Following extraction, RNA was precipitated with 
isopropanol and 3M sodium acetate and then quantitated with a NanoDrop 
spectrophotometer (ThermoFisher, Wilmington, DE, USA). Further analysis was 
performed on samples with a 260/280 ratio greater than 1.8 and a 260/230 ratio greater 
than 2.0. RNA was DNase treated using the DNA-free kit (Applied Biosystems). Two 
micrograms of RNA were then reverse transcribed to cDNA using TaqMan Reverse 
Transcription Reagents; 5µL 10x TaqMan RT buffer, 11µL 25mM MgCl2, 10µL 
deoxyNTPs Mixture (2.5mM), 2.5µL oligo d(T)16 primers, 1.25µL MultiScribe Reverse 
Transcriptase (Invitrogen). Reagents were added to RNA samples before being placed in 
the MasterCycler thermocycler (Eppendorf). The cycle started with a 10-minute 
incubation period at 25°C, followed by reverse transcription for 30 min. at 48°C and 
inactivation for 5 minutes at 95°C. The resulting complimentary DNA was amplified 
with SYBR Green Master Mix (Applied Biosystems) using the ViiA 7 Real-Time PCR 
System (Applied Biosystems, Grand Island, NY, USA) under the following cycle 
conditions: incubation for 10 minutes at 95°C, 45 cycles of 15 seconds at 95°C and 60 
seconds at 60°C. All reactions were performed in duplicate with GAPDH and B2M as 
reference genes due to reported stability in analyzed tissue types [86-88]. ∆Ct values 
were analyzed. Primers were generated using Primer Blast from the National Center for 
Biotechnology Information (/www.ncbi.nlm.nih.gov/tools/primer-blast/) (Figure 1). 
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RNA Sequencing: 
Isolation of RNA from testis and liver was performed using RNeasy Mini Kit 
(Qiagen, Gaithersburg, MD, USA) per manufacturer’s instructions. RNA from mare 
(n=2) and fetal (n=2) livers were pooled together into a single sample. RNA extracted 
from stallion (n=3) testes were pooled. Integrity, purity and concentration of RNA was 
analyzed by NanoDrop (Thermo Fisher Scientific; Hampton, NH) and Bioanalyzer 
(Agilent, Santa Clara, CA, USA). All samples had a 230/260 ratio > 1.8, a 260/280 ratio 
> 2.0 and an RNA integrity number > 8.0. 
Library preparation was performed using TruSeq mRNA Sample Prep kit 
(Illumina, San Diego, CA USA), as per manufacturer’s instructions. Libraries were 
quantitated via qPCR and then sequenced on a HiSeq 4000, using a HiSeq 4000 
sequencing kit, version 1 (Illumina), generating 150 bp paired-end reads. Resultant 
FASTQ files were demultiplexed with the bcl2fastq v2.17.1.14 Conversion software 
(Illumina). 
Following sequencing, reads were trimmed for adapters and quality using 
TrimGalore v0.4.4 (Babraham Bioinformatics; www.bioinformatics.babraham.ac.uk), 
with quality evaluated via FastQC v0.11.4 (Babraham Bioinformatics). Reads were 
mapped to EquCab2.0 using STAR-2.5.2b (github.com/alexdobin/STAR) using 
coordinates from NCBI. Presence or absence of reads was determined visually using 
Integrated Genome Viewer v2.3.97 (The Broad Institute; https://data.broadinstitute.org). 
Immunohistochemistry: 
Staining for immunohistochemical analysis was performed using an automated 
staining system (Bond-maX; Leica Biosystems, Newcastle Upon Tyne, UK). The 
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primary antibody used for the detection of ABP was mouse monoclonal and generated 
using amino acids at the C-terminus of human SHBG (sc-377031, Santa Cruz) and 
diluted to 1:100 using Bond Primary Antibody Diluent (Leica Biosystems; Wetzlar, 
Germany). Slides were made with 5µm sections of paraffin embedded tissues. The 
staining protocol followed was that provided by the manufacturer (Leica Biosystems) as 
previously described [89].The slides underwent an initial automated dewaxing and 
rehydration step before undergoing a heat-induced (20 min at 100°C) antigen retrieval 
using an EDTA-based ready-to-use solution with a pH 8.8 (Leica Biosystems). Following 
antigen retrieval, slides were incubated with 3% hydrogen peroxide (5 minutes), diluted 
primary antibody (15-30 minutes), a post-primary blocking reagent containing 3% BSA 
(minimize nonspecific polymer binding, 8 minutes), horseradish peroxidase-labeled 
polymer (8 minutes), and diaminobenzidine substrate (10 minutes). Washing took place 
between each step using Bond Wash Solution 10x diluted to 1x working solution with 
distilled water.  
Testosterone Analysis: 
Serum from pregnant mares and stallions was analyzed for total and free 
testosterone concentrations. Total testosterone was measured using an in-house ELISA as 
described below. Free testosterone was analyzed using a commercially available 
radioimmunoassay per manufacturer’s instructions (Siemens Free Testosterone Coat-A-
Count Kit; Dublin, Ireland). 
Total Testosterone Analysis 
The testosterone antibody (Clinical Endocrinology Laboratory, University of 
California, Davis, California, USA) was diluted in sodium bicarbonate buffer (Sigma, St. 
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Louis, MO) to a dilution of 1:9,000. Fifty microliters of diluted antibody were added to 
each well of a 96-well plate, with the exception of two wells to be used as blank controls. 
The plates were then sealed tightly and stored at 4°C for at least 48 hours or until needed.  
Two hundred microliters of serum were mixed with 1 mL of diethyl ether (Fisher 
Scientific; Hampton, NH) in a borosilicate glass tube and vortexed for 45 sec. The tubes 
were then place in liquid nitrogen until the aqueous phase was frozen, and the ether layer 
was then decanted off into a fresh borosilicate glass tube and left in a fume hood 
overnight to allow evaporation of the ether solvent. Samples were reconstituted in 
phosphate buffered saline containing 0.1% bovine serum albumin (Sigma, St. Louis, MO) 
and horseradish peroxidase (HRP) conjugated testosterone (Clinical Endocrinology 
Laboratory, University of California, Davis, CA) at a dilution of 1:60,000. 
 Standard stocks were developed by weighing out lyopholized testosterone 
(Steraloids: Newport, RI) and dissolving it methanol. This was then used to create a nine-
point standard curve between 0.02 and 10 ng/mL. The appropriate volume of stock 
solution was pipetted into clean boroslicate glass tubes and allowed to dry. One milliliter 
of the HRP-conjugated buffer was added to the standard tubes, and they were vortexed 
for 30 seconds for reconstitution. Samples were reconstituted in 250 µL of HRP-
conjugated buffer and vortexed for 15 seconds. 
 Plates that were previously coated in antibody were used for standard and sample 
plates. All plates were washed before use. For the standard plate and sample plates, 50 
microliters of phosphate buffered saline containing 0.1% bovine serum albumin were 
added to each well. To the standard plate, 50 microliters of HRP conjugated buffer were 
added to the first three and last three columns with 50 microliters of each standard added 
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in replicates of eight across the center. To the sample plates, HRP conjugated buffer was 
added as previously mentioned with 50 µL of each sample added in duplicate in the 
center of the plate. Pooled stallion serum was used as a high testosterone control with 
pooled gelding serum used as a low testosterone control. 
 All plates were incubated for 2 hours at room temperature and then washed three 
times. One hundred microliters of substrate (2, 2’-azino-bis-3-ethylbenzothiazoline-6-
sulfonic acid (ABTS) in citric acid with H2O2; Sigma, St. Louis, MO) was added to each 
well across all plates. Plates were then incubated for an hour before the addition of 100 
µL of stop solution to each well (EDTA in hydrofluoric acid; Sigma, St. Louis, MO). 
Plates were read using the Epoch microplate spectrometer (BioTek; Winooski, VT).  
Heterologous SHBG Immunoassays: 
SHBG analysis was performed using a heterologous, commercially-available, 
human SHBG assay (human SHBG Quantikine ELISA Kit (R&D Systems; Minneapolis, 
MS)) and a chemiluminescence SHBG assay (Immulite 2000 platform; Seimens Medical 
Solutions USA)). Analysis was performed using stallion, open mare, and pregnant mare 
serum and manufacturer’s instructions were followed. 
Statistical Analysis: 
 Statistical analyses were performed using JMP software (JMP ® , Version 12. 
SAS Institute Inc., Cary, NC). Data was checked for equal variance using Bartlett’s Test. 
For qPCR, mRNA expression was analyzed using a one-way ANOVA and is represented 
as ∆Ct or the difference between the Ct of the housekeeping genes and the gene of 
interest.  Total testosterone concentrations following ultrafiltration were analyzed by way 
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of a nonparametric Wilcoxon’s Rank Test. All data are represented as mean ± SEM 
unless otherwise specified. The level of significance was set to 0.05. 
Results 
Experiment 1: 
When compared to all mare, fetal and stallion livers, significant expression of 
ABP was seen in all testis samples using qPCR (P<0.001) (4.179 ± 0.591). Amplification 
seen in the equine liver samples was considered to be negligible, due to all Ct values 
being > 36 (16.480 ± 0.632) (Figure 2). Using RNA sequencing, no transcript for SHBG 
was found (Chr 11: 50589067..50591923) in the pooled mare/fetal liver or in the stallion 
liver (FPKM = 0). A transcript was found in the pooled stallion testes, indicating the 
presence of ABP (FPKM = 2.3307). This transcript had five exons compared to the 
predicted protein transcript in EquCab2.0, which shows eight exons (Figure 3).   
Experiment 2: 
Equine heart, liver, and pre-, peri-, and post-pubertal testes were all evaluated 
with immunohistochemistry using a mouse anti-human SHBG antibody (Figure 4). No 
positive staining for ABP/SHBG was seen in the equine heart, as expected. ABP was 
immunolocalized in the seminiferous tubules, Sertoli cell, interstitial spaces, and Leydig 
cells of all examined testes using IHC. Staining in the pre-pubertal testes looked to be 
slightly less localized than that of the peri- and post-pubertal testes. No positive staining 
was visible in the liver, indicating the absence of the SHBG protein (Figure 4).  
Experiment 3: 
In the stallions stimulated with hCG, there was an increase in both free and total 
testosterone in serum following the injection (Figure 5). Even with this increase, the free 
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testosterone was still significantly lower (p < 0.0001) than the total testosterone in 
circulation. In pregnant mares a large increase of testosterone was detected using the total 
testosterone immunoassay as expected during pregnancy (Figure 6). However, regardless 
of gestational time point, no testosterone was detected with the free testosterone RIA in 
the pregnant mare (p < 0.0001).  
The heterologous SHBG assays were utilized due to the 79% homology between 
human SHBG and equine SHBG. Cross reaction between the equine SHBG and antibody 
was possible. However, all samples fell below the level of detection in both of the 
heterologous SHBG assays. All controls and standard curves fell within the range set by 
the manufacturer protocol.  
Discussion 
This study has shown that ABP is in fact present in stallion testes and that 
testosterone circulates bound to a protein in the horse. Until now, some of the only 
information regarding ABP in the horse was that it was not detected in equine seminal 
plasma [58]. This did not necessarily indicate that the protein was not present within the 
testes. There are multiple species in which the protein is present within the testis, but 
taken up in the epididymis [58]. While epididymal uptake has yet to be studied in the 
stallion, it would seem that this is the case, because the protein is not present in seminal 
plasma but both mRNA and protein are detectable for ABP in the testes.  
ABP was found in the testis of the stallion using three separate methodologies. 
ABP was first seen in stallion testes through cDNA amplification using qPCR. This 
amplification was seen in all of the testis samples, while amplification in any of the tested 
liver samples proved to be negligible. However, this did not necessarily indicate that 
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SHBG was not present in equine liver. Regarding ABP and SHBG in the rabbit, one 
study found that the amount of ABP present in the testis increased into adulthood, 
whereas the amount of SHBG present in the liver decreased [90].  
When looking at the data generated through RNA sequencing, it is shown that the 
transcript for ABP is present at the predicted locus in the testis. It is also shown that while 
this gene was predicted to contain eight exons as in humans (Hammond, et al. 1989), 
whereas the actual equine transcript only contains five exons. Variation in exon number 
is seen across species. While human SHBG contains eight and equine ABP contains five, 
bovine SHBG contains twelve exons [46]. However, this transcript was not present at the 
predicted locus in the liver, which explains the lack of SHBG amplification using qPCR.  
 Sertoli cells are the site of production for ABP in most mammals following 
stimulation from FSH [54]. From there, roughly 80% of ABP produced remains in the 
seminiferous tubules while 20% is secreted into the interstitial spaces [56]. The findings 
of this study coincide with previously reported ABP localization. Through the use of 
immunohistochemistry, it is shown that ABP is present in the seminiferous tubule lumen 
as well as in the interstitial spaces of the pre- and peri-pubertal colt testis and post-
pubertal stallion testis. IHC failed to show any indication of SHBG in the liver, which 
would further indicate its absence in the horse. Although it was shown that the gene for 
SHBG was present in the equine transcriptome, it was not specified as to where this 
transcript was located. The study was conducted by sequencing 43 pooled equine tissues 
with the testis being one of them [84]. The results of this current investigation indicate 
that the SHBG transcript found was that of ABP. 
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When comparing the free and total testosterone ELISA data in pregnant mares 
and stallions stimulated with hCG, it is apparent that testosterone is circulating bound to a 
carrier. In pregnant women, it has been shown that only 0.23% of the testosterone present 
during gestation is unbound [91] and this is evident in the pregnant mare as well. 
Although all samples fell below the level of detection using the heterologous SHBG 
assays, it was thought that equine SHBG could have failed to cross react despite having 
79% homology with human SHBG. In order for there to be a high chance of cross 
reactivity, the two species need to have 80% homology [92]. However, data from qPCR 
and RNA sequencing shows that the transcript for SHBG is not present in the liver of the 
horse, which explains the lack of detection using the assays. This also supports previous 
claims of the lack of SHBG found in equine serum  [82, 85].   
In most species, androgens circulate in three forms; free, bound to SHBG, and 
bound to albumin [21]. Humans, little brown bats, goats, sheep, cattle, some fish and 
amphibians are just a few that have SHBG as an androgen carrier in circulation [13, 16, 
78, 79]. In species that do not have SHBG, such as elephants and donkeys, androgens 
primarily circulate bound to albumin [81]. While this investigation has provided evidence 
of androgens circulating bound to a protein, it cannot yet be concluded that this protein is 
albumin. It has been reported that testosterone circulates bound to progesterone-binding 
globulin in the horse [93]. A study conducted by [91] found that while testosterone 
circulates bound to SHBG and albumin, a small percentage can be bound to 
corticosteroid-binding globulin (CBG). Further research needs to be conducted in order to 
identify the specific steroid carrier for the horse; however, we can confidently conclude 
that there is a carrier present.   
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This study was able to characterize the expression of ABP in the equine testis, 
which had not been previously reported. ABP was shown in the seminiferous tubule 
lumen and in the interstitial spaces of the testis of pre- and peri-pubertal colts, as well as 
post-pubertal stallions through IHC. Expression was also found in the testis trough qPCR 
and the gene transcript identified with RNA sequencing. This study also provided 
evidence of a steroid carrier in circulation in both stallions and pregnant mares. Although, 
it has been concluded that SHBG is not the carrier in circulation, due to the lack of 
transcript in the equine liver.  
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Figures 
Primer Direction Sequence 
Forward TCTTGGCTCAGCTTTCACCT 
Reverse CTGGTTCAAGACCACCCTGG 
 
Figure 3.1: ABP/SHBG primers. Primers were generated using Primer Blast from the 
National Center for Biotechnology Information (/www.ncbi.nlm.nih.gov/tools/primer-
blast/). 
 
 
 
 
Figure 3.2: ABP/SHBG amplification with qPCR. Bar graph showing mean ∆ Ct ± 
SEM of SHBG expression in mare, fetal and stallion liver (n=7) and testis (n=7). 
GAPDH and B2M were used to calculate ∆ Ct and significance was set to P < 0.05. 
Significant difference is indicated using *.  
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Figure 3.3: ABP transcript in comparison to well-known SAT2 transcript. Sashimi 
plots generated using Integrated Genomics Viewer showing SHBG transcript using 
EquCab2.0 (Chr 11: 50589067..50591923) in comparison to the well-defined transcript 
for spermidine/spermine N1-acetyltransferace family member 2 (SAT2). The transcript 
for SAT2 is visible in all samples. No transcript is seen at the location for SHBG in 
pooled mare/fetal liver (A) and stallion liver (B). A 5-exon transcript is seen at the locus 
for SHBG in the pooled stallion testis (C), indicating the presence of ABP.  
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Figure 3.4: Immunolocalization of ABP. Immunohistochemical staining in equine heart 
(A), liver (B), pre-pubertal colt testis (C & D), peri-pubertal colt testis (E), post-pubertal 
stallion testis (F), The equine heart (A) was utilized as a negative control. Positive 
staining for ABP/SHBG is visualized with brown stain. Slides were stained with 1:100 
diluted antibody and viewed at 20x magnification. 
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Figure 3.5: Comparison of free and total testosterone in hCG stimulated stallions. 
Graph showing the comparison of free and total testosterone in stallions (n=4) that 
received an injection of hCG (5000 IU). Free testosterone is represented in pg/mL and 
total testosterone is represented in ng/mL. Free testosterone is shown in blue and total 
testosterone is shown in red. Total testosterone was significantly higher than free 
testosterone at all measured time points (p < 0.0001). 
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Figure 3.6: Comparison of free and total testosterone in pregnant mares. Graph 
showing the comparison of free and total testosterone in the pregnant mare (n=18). 
Testosterone is represented in ng/mL. Free testosterone is shown in blue and total 
testosterone is shown in red. Total testosterone was significantly higher than free 
testosterone at all measured time points (p < 0.0001). 
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Chapter 4: Characterization of thyroxine-binding globulin in the horse and 
evaluation of circulating levels in response to increased androgen concentrations 
B.O. Fleming, A. Esteller-Vico, S.E. Loux, K.E. Scoggin, B.A. Ball 
Abstract 
 In human and equine sports, it is known that competitors sometimes administer 
foreign substances in order to enhance their performance. Currently in equine athletes, 
testing for these substances is accomplished to the specific identification of the substance 
administered through the use of gas chromatography/liquid chromatography tandem mass 
spectrometry While this methodology is very sensitive, if a novel substance is 
administered it can bypass detection. The World Anti-Doping Agency has proposed the 
use of biomarkers in human athletics as a way to indirectly measure anabolic androgenic 
steroid abuse. One protein that is significantly affected by this administration is 
thyroxine-binding globulin (TBG). TBG has been identified in the horse but has yet to be 
fully characterized. This study measured TBG concentrations in relation to seasonal 
changes [mares (n=5), stallions (n=5), geldings (n=5)] and across varying reproductive 
statuses [fillies (n=3), colts (n=3), non-pregnant mares (n=5), pregnant mares (n=5), 
stallions (n=5), geldings (n=5)] and ages. TBG concentrations were also analyzed 
following exogenous androgen administration (Stanozolol) and increased endogenous 
androgen production (hCG or aromatase inhibitor administration). TBG concentrations 
did not differ significantly across seasons in mares, stallions, or geldings. There was no 
significant effect of reproductive status, sex, or age on circulating TBG concentrations. 
Stanozolol administration did not significantly alter TBG concentrations. Increased 
endogenous androgen production via hCG administration in stallions and aromatase 
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inhibitor (Letrozole) administration in pregnant mares did not have an effect on 
circulating TBG concentrations. While this investigation did not yield any effects on 
TBG concentrations following alteration of androgen levels, it is possible that more 
potent steroids and higher concentrations could illicit a noticeable change.  
Introduction 
Drastic alterations in the concentration of circulating androgens cause many 
physiological changes in the body [7]. One notable effect, is the measurable change in 
circulating levels of various carrier proteins [11]. In human sports, the changes in these 
protein levels has been used to help identify whether or not athletes have been 
administered performance enhancing substances, specifically anabolic androgenic 
steroids (AAS). This method of identification is referred to as the Athlete Biological 
Passport, where an athlete’s own reference range for a specific protein is used to 
determine if there is any significant deviation from their norm [3]. These proteins are 
referred to as biomarkers and have eased the identification of illegal substance use in 
human athletes [2].  
In equine athletics, the current testing methods for banned substances are 
expensive and require the identification of the specific substance administered [1]. This 
can cause novel substances referred to as “designer steroids” to go undetected, allowing a 
competitor to continue competing following the administration of a performance 
enhancing substance [3]. Currently, there are no biomarkers for the use of AAS in the 
horse. However, a carrier protein of interest that has been shown to significantly decrease 
in circulating levels following AAS administration in humans is thyroxine-binding 
globulin (TBG) [15].  
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TBG concentrations have been shown to react to changes in steroid 
concentrations in human athletes and in dogs [15, 94]. A study conducted by Alén in 
1987, showed that following self-administration of exogenous androgens, human athletes 
saw as much as an 80% reduction in circulating levels of TBG [15]. This reduction 
remained throughout the administration period and took several weeks following 
withdrawal to return to pre-administration levels. Just as androgens cause a decrease in 
TBG levels, estrogens have been shown to significantly increase TBG levels [95]. 
Pregnant women and women taking birth control have higher circulating levels of TBG 
compared to non-pregnant women and those not on contraceptives [68, 95, 96]. A study 
has shown that TBG could be measured as an indicator as to whether or not women have 
been taking their prescribed contraceptives as instructed [95]. 
Circulating androgen concentrations can be changed by way of a few different 
methods [97]. The first method is by administering an exogenous androgen source such 
as anabolic androgenic steroids [98, 99]. This increases the concentration of androgens in 
circulation without causing the body to increase its own androgen production. The second 
method is by increasing endogenous production of androgens. A common way of doing 
this is by administering human chorionic gonadotropin (hCG) causing an increase in LH 
production, which leads to increased testosterone production [100, 101]. Another way to 
endogenously increase androgen production is by inhibiting testosterone’s aromatization 
to estrogen. This is accomplished by orally administering an aromatase inhibitor such as 
Letrozole [97, 102]. Regardless of the method utilized to increase androgens in 
circulation, this increase should result in a decrease in circulating TBG concentrations.  
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TBG binds thyroxine (T4) and triiodothyronine (T3) [103]. It is produced and 
secreted in the liver and is affected by exogenous steroid administration by way of post-
translational modifications [68].  It has been shown that the administration of exogenous 
estrogens increases the sialic acid content of TBG which reduces its clearance rate in the 
liver, therefore increasing the circulating concentrations of TBG [67]. Currently, there are 
no studies that have specifically investigated the mechanism in which exogenous 
androgens decrease TBG concentrations. However, it is postulated that androgens would 
decrease the sialic acid content of TBG, resulting in an increased clearance rate in the 
liver and decreasing TBG concentrations in circulation [68].   
 While TBG has been verified in the horse [65], there were no other studies 
identified which addressed this protein or its normal circulating levels in the horse. The 
hypotheses for this study are that TBG concentrations will not differ between sexes or 
ages, concentrations will increase throughout gestation, and concentrations will 
significantly decrease following an increase in circulating androgens. The objectives of 
this study are; 1) to characterize normal circulating concentrations of TBG across 
seasons, as well as the effects of reproductive status, sex, and age, 2) to examine the 
effects of increased androgen concentrations via exogenous androgen administrations 
(Stanozolol) in stallions and increased endogenous androgen production (hCG 
administration in stallions and Letrozole administration in pregnant mares).  
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Materials and Methods 
Experiment 1: Characterization in circulation  
Serum Collection: 
Animals were kept in pastures and provided grain daily per University of 
Kentucky Institutional Animal Care and Use Committee protocol (#2016-2358). Bi-
weekly blood samples (20mL) were collected from 28 horses of varying ages and 
reproductive statuses beginning in September 2016 and ending in August 2017 [ 3 colts, 
3 fillies, 5 pregnant mares (>3 years), 5 open mares (> 3 years), 5 stallions (>3 years), 5 
geldings (2 years)]. Samples were drawn via jugular venipuncture using non-heparinized 
tubes (Butler Animal Health Supply, Dublin, OH) and spun down at 1,200 RCF for 20 
minutes at room temperature. The separated serum was then collected, aliquoted and 
stored at -20°C until analysis via ELISA. 
Experiment 2.1: Stanozolol Administration 
Stallions (n=6), non-pregnant mares (n=6), and geldings (n=6) were randomly 
assigned to treatment groups [Control (n=9); Treated (n=9)] with three stallions, three 
mares, and three geldings per group. All received a single intramuscular injection of 1.5 
mg/kg Stanozolol (Steraloids; Newport, RI) in an aqueous solution (Doc Lane’s 
Veterinary Pharmacy; Lexington, KY) each week for 3 weeks [99]. Stanozolol injections 
were administered on days 0, 7 and 14. Blood was collected prior to the first injection 
(day 0) and for the following 7 days. Blood samples were collected prior to the remaining 
2 injections (day 7 and day 14) and 28, 42, 70, and 99 days after the final injection. Blood 
samples were processed and stored as mentioned above. Animals use was approved by 
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the University of Kentucky Animal Use Care and Use Committee (Protocol #: 2016-
2358). 
Experiment 2.2: hCG Administration 
The samples analyzed for this study were obtained from a previously conducted 
study. Briefly, stallions (n=4) received single intravenous injection of 5,000 IU of hCG 
(Choluron, Intervet Inc, USA) as per standard protocol (University of Kentucky IACUC 
#2013-1088). Four additional stallions were utilized as controls. Blood was collected 
from the treated stallions and control stallions prior to injection as well as 96 hours and 
10 days post injection. Blood samples were processed and stored as above. 
Experiment 2.3: Letrozole Administration 
All animal use was approved by University of Kentucky Institutional Animal 
Care and Use Committee protocol (#2013-1067). Serum samples for this experiment 
were obtained from a previously published study [102]. Briefly, twelve pregnant mares 
were randomly assigned to groups [control (n=6); treated (n=6)] at 240 days of gestation. 
Mares in the treatment group were orally administered 500 mg of letrozole (Aurum 
Pharmatech LLC, Howell, NJ 07731) every 4 days until parturition. Control mares 
received and oral placebo at the same interval as the mares treated with Letrozole. 
Blood samples were collected via jugular venipuncture 1 week before treatment 
began and on the day of treatment administration until day 315 of gestation. Blood 
samples were then collected daily until parturition. Serum was processed and stored as 
above. 
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TBG ELISA: 
 Serum was analyzed using the equine specific Thyroxine-Binding Globulin 
ELISA kit (MyBioSource, Inc.; San Diego, CA). Samples were run in singlet and all 
manufacturer instructions were followed. Reagents were brought to room temperature 30 
minutes prior to use in corresponding assay step. When protocol called for protection 
from light, all ceiling lights were turned off in the laboratory and remained off until assay 
completion. Pooled serum from pregnant mares (n=5) and pooled serum from geldings 
(n=5) were used as low and high controls. Inter-assay CV’s were 13% and 12% with 
intra-assay CV’s being 8% and 13% respectively. 
Statistical Analysis:  
 Statistical analyses were performed using JMP software (JMP ®, Version 12. SAS 
Institute Inc., Cary, NC). All data sets were analyzed using nonparametric analysis via 
Wilcoxon Each Pair Test. All data are represented as mean ± SEM unless otherwise 
specified. The level of significance was set to 0.05. 
Results 
Experiment 1 
 There were no significant differences between TBG concentrations in geldings, 
nonpregnant mares, or stallions throughout the year of bimonthly serum collection 
(Figure 4.1; p>0.05). Reproductive status did not have a significant effect on circulating 
concentrations of TBG (Figure 4.2; p>0.05). Gestational age did not have a significant 
effect on TBG concentrations in pregnant mares (Figure 4.3; p>0.05). TBG 
concentrations did not significantly differ throughout the first year of life in colts and 
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fillies (Figure 4.4; p>0.05).  There were no significant differences in TBG concentrations 
based on age of the animal (Figure 4.5; p>0.05). 
Experiment 2 
 Exogenous androgen administration with Stanozolol did not significantly alter the 
levels of TBG in circulation of geldings, mares, or stallions when compared to the control 
group (Figure 4.6; p>0.05).  Increasing endogenous levels of androgens via hCG 
administration did not have a significant effect on TBG concentrations when compared to 
the control stallions (Figure 4.7; p>0.05).  See Figure 3.5 for reference of testosterone 
increase following hCG administration. Increasing endogenous androgens in the 
circulation of pregnant mares by inhibiting testosterone aromatization to estrogen via oral 
administration of Letrozole did not have a significant effect on TBG concentrations when 
compared to the control group (Figure 4.8;  p>0.05).  
Discussion 
 TBG is a carrier protein found in circulation in most vertebrates that is shown to 
be greatly affected by changes in circulating sex hormones [15, 68, 95]. While this 
protein has the potential to be utilized as a biomarker for illegal substance administration 
in athletes, it has not been as extensively characterized as other carrier proteins that could 
serve the same purpose, such as sex hormone-binding globulin. Although TBG has 
previously been verified in the horse [65], there is no other literature regarding this 
protein other than confirming its existence. One objective of this study was to 
characterize levels of TBG in horses based on factors such as seasonal change, 
reproductive status, age, and sex.  
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 Horses are seasonal breeders that experience changes in circulating hormone 
concentrations throughout the year [104, 105]. Given the many previously published 
reports on TBG concentrations being affected by endogenous changes in hormone 
concentrations, it was hypothesized that TBG concentrations would significantly differ 
throughout the year in horses. Surprisingly, time of year did not have a significant effect 
on the circulating levels of TBG in any of the animals that were analyzed across season  
 Given the difference in testosterone and estrogen concentrations between males 
and females [21, 22], it could be assumed that TBG concentrations would differ based on 
sex and reproductive status. However, literature in humans has shown that there is no 
significant difference in TBG concentrations based on sex [106]. Males and females have 
roughly the same circulating concentrations. Also, these concentrations are not affected 
by age in post-pubertal humans [106]. Based upon our data, these findings hold true in 
the horse. There were no differences in TBG levels between colts, fillies, geldings, 
nonpregnant mares, pregnant mares, or stallions.  
 Mares experience a rise in estrogen concentrations throughout pregnancy [102] 
just as humans do. In pregnant women, this increase in estrogens is associated with an 
increase in TBG concentrations [107-109]. TBG levels also rise in women who are taking 
oral contraceptives [68, 95]. Our data in the horse, did not identify any significant 
differences between any of the analyzed gestational time points in pregnant mares or 
compared to nonpregnant mares.  
It is unclear as to why there are no differences in TBG concentrations throughout 
gestation in the pregnant mare. When examining the data in Figure 3, it looks as though 
there is an increase in TBG concentrations as gestation progresses. However, the standard 
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errors in this data set are obviously quite large and could be preventing any tendency or 
statistical differences from being reported during analysis. Increasing the number of 
pregnant mares in the sampling group could decrease the standard error size and improve 
the statistical analysis.  
 A study conducted by Elmlinger in 2001 looked into changes in T4, T3, free T3, 
free T4, TBG and thyroid-stimulating hormone (TSH) in humans from birth to adulthood 
[110]. This study examined males and females from the age of 1 day to 19 years and 
grouped them according to their stage of sexual maturation based on the Tanner stages 
[111]. It was found that TBG concentrations increased by around 60% following the 
neonatal period and began to decrease around puberty. TBG was the only thyroid 
parameter examined to show a significant decrease between Tanner stages 1 and 5 in both 
males and females, indicating that TBG concentrations decreased as both males and 
females progressed to and through puberty.  
 As previously mentioned the current study has shown that there are no significant 
differences between ages in horses, which is line with findings in humans [106]. The 
current study also investigated the possibility of changes in TBG concentrations in fillies 
and colts during their first year of life. No significant differences were found between any 
of the time points analyzed during the first year of life in fillies and colts. Sampling of 
these animals began when they were between 12 – 15 weeks of age. It is possible that 
horses could also experience an increase in TBG concentrations during their neonatal 
period [110]; however, the current study did not begin sampling until after this stage of 
their lives.  
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 The second objective of this study was to determine if increased androgen 
concentrations, induced by exogenous or endogenous means, could illicit a significant 
change in circulating TBG levels. Stanozolol administration was a way to increase 
androgens in circulation exogenously. In human body builders, it is commonly known 
that this administration causes a significant decrease in TBG concentrations [15, 68]. This 
does not seem to be the case in the equine model at a dose of 1.5 mg/kg once a week for 
three weeks. TBG concentrations were not significantly affected by the administration of 
stanozolol. Stanozolol is a weak AAS and has some estrogenic properties, which could 
contribute to the lack of effect observed [112]. Also, most athletes who abuse AAS use 
some sort of cocktail containing multiple steroids at high concentrations [5, 12, 15].  
This is the first study to investigate the effects of exogenous androgen 
administration on TBG concentrations in the horse. When AAS are administered with the 
intent of enhancing performance, they are given at a concentration much higher than that 
intended for therapeutic use [98]. The current investigation tripled the amount of 
stanozolol administered by Soma et al. in 2000 in an attempt to illicit a response in TBG 
concentrations [99]. It is possible that this steroid alone and at the given dose was not 
enough to elicit a response in TBG concentrations.  
 The current study investigated two separate means of increasing endogenous 
androgen production through hCG administration in stallions and by preventing 
testosterone aromatization to estrogen in pregnant mares. Both of these methods 
produced significant increases in testosterone concentrations in circulation [102]; 
however, no significant changes in TBG concentrations were observed. These results do 
not coincide with reported findings in humans.  
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 hCG administration caused an acute increase in testosterone levels that returned 
to baseline by 10 days post injection (see Figure 3.5). It is possible that this limited time 
increase in testosterone production was not long enough to effect TBG levels in 
circulation. If an athlete is abusing anabolic steroids, they will continue to administer the 
AAS for a long enough period of time to be able to experience the desired results rather 
than rely on a single injection [12, 15].  
 When examining the effects of sex or age, TBG concentrations in the horse have 
been shown to follow somewhat of the same pattern as reported in humans. It is possible 
that there could be an increase in TBG during the equine neonatal period, but this is 
beyond the scope of this study and would require further investigation. The findings of 
this study differ in the effects of gestation and increased androgen concentrations on TBG 
levels when compared to human literature. There is little literature regarding TBG in 
species other than the human, which is why this report focuses on humans as a point of 
comparison. It is unknown why the horse has failed to show the expected patterns and 
responses in TBG concentrations. This point deserves further investigation. It is possible 
that the lack in significance seen is due to the large standard errors present in all of the 
data sets. There is the potential that increasing the sample sizes for these analyses could 
decrease the standard errors and give an improved understanding of TBG characterization 
in the horse.   
 There are many future studies that could stem from these results. A study that 
includes more potent AAS at higher concentrations and for longer administration periods 
would give better insight into the effects of exogenous steroid administration on TBG 
concentrations. Also, the effects of multiple injections of hCG rather than a single 
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injection would be worth examining. Currently, the concentrations of T3 and T4 are 
being examined from the horses that were included in the Stanozolol study. The analysis 
of these hormones could give additional insight into the effects of exogenous androgen 
administration. While humans experience of brief effect on T4 concentrations following 
AAS administration [113], this hormone quickly returns to normal levels and any lasting 
effects cannot be detected. Whether or not this is the case in the horse has yet to be 
investigated.  
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Figures 
 
 
Figure 4.1: Seasonal variation in TBG concentrations. Bi-monthly concentrations of 
TBG in geldings (n=5), nonpregnant mares (n=5), and stallions (n=5). Data are 
represented as mean ± SEM. There were no significant differences seen between any of 
the months nor the grouping of the horses.  
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Figure 4.2: TBG concentrations based on reproductive status. Box plot showing TBG 
concentrations based on reproductive status; colt (n=3), filly (n=3), gelding (n=5), 
nonpregnant mare (n=5), pregnant mare (n=4), stallion (n=5). There were no significant 
differences seen between any of the reproductive statuses.  
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Figure 4.3: TBG concentrations based on gestational age. TBG concentrations in 
pregnant mares (n=5) based on gestational age. Time point 0 indicates before pregnancy. 
Data are represented as mean ± SEM. There are no significant differences between 
concentrations of TBG during gestation.  
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Figure 4.4: TBG concentrations during the first year of life in colts and fillies. TBG 
concentrations during the first year of life in colts (n=3) and fillies (n=3). Colts are 
represented in blue and fillies are represented in red. Data is represented as mean ± SEM. 
There were no significant differences seen between any of the months or the sexes of the 
animals.   
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Figure 4.5: TBG concentrations based on age. Group A contained horses < 2 years of 
age (n=8), Group B contained horses between 3 – 9 years of age (n=5), Group C 
contained horses between 10 – 19 years of age (n=6), Group D contained horses between 
20 – 25 years of age (n=3). There was no significant difference between TBG 
concentrations in any of the age groups. 
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Figure 4.6: Effect of stanozolol administration on TBG concentrations. The control 
group (n=9) is represented in blue and the treated group (n=9) is represented in red. Data 
is represented as mean ± SEM. Day 0 indicates baseline concentrations prior to 
administration. The drug was administered after blood collection on days 0, 7, and 14. 
There were no significant differences in TBG concentrations between the control and 
treated groups at any of the analyzed time points. 
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Figure 4.7: Effect of increasing endogenous testosterone production via hCG 
administration on TBG concentrations. The control group (n=4) is represented in blue 
and the treated group (n=4) is represented in red. Data is represented as mean ± SEM. 0 
hours indicates baseline concentrations prior to hCG administration. There were no 
significant differences in TBG concentrations between the control and treated groups at 
any of the analyzed time points. 
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Figure 4.8: Effect of testosterone aromatization inhibition via letrozole 
administration on TBG concentrations. The control group (n=6) is represented in blue 
and the treated group (n=6) is represented in red. Data is represented as mean ± SEM. 
Baseline concentrations were collected at 8 months of gestation prior to drug 
administration. There were no significant differences in TBG concentrations between the 
control and treated groups at any of the analyzed time points during gestation. 
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Chapter 5: Summary and Conclusion 
 
 A biomarker for anabolic androgenic steroid (AAS) abuse in the horse would 
allow for a much wider array of AAS detection in equine athletes. While this 
investigation did not yield a definitive biomarker, it is a start into a new and necessary 
realm of research. The characterization of carrier proteins affected by AAS 
administration would be ideal for an indirect indicator of substance abuse.  
 Although this study has further confirmed the absence of SHBG in equine 
circulation, it did indicate the presence of a carrier protein for androgens. Albumin is 
already known to be present in circulation in the horse and is known to bind to sex 
hormones. However, it cannot be concluded that albumin is the only carrier protein 
present. Speculation into the identity of other carrier proteins is beyond the scope of this 
study but deserves to be investigated.  
This study was also able to identify the presence of ABP in stallion testes, even 
though the absence of ABP in stallion seminal plasma has been reported. It would 
therefore be assumed that ABP would be absorbed by the epididymal epithelium; 
however, this concept deserves further investigation as well. Seeing as ABP remains in 
the testes in most species, it would not be a viable biomarker for AAS administration in 
the horse. Although ABP has been reported in circulation in the rat, the absence of a band 
around the molecular weight of ABP (44kDa) when examined via ammonium sulfate 
precipitation, DHT affinity chromatography and western blot, indicates that ABP is not 
secreted into circulation in the stallion (see Appendix A). Further investigation into the 
actual peptide sequence of the protein is necessary for confirmation of secretion 
inhibition.  
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TBG was detected and measured through the use of the Horse Thyroxine-Binding 
Globulin Assay kit from MyBioSource. Although this study was unable to detect any 
significant differences in TBG concentrations following changes in circulating levels of 
androgens, this does not necessarily mean that TBG would not be a viable biomarker for 
AAS abuse in the horse. Increasing the administered dose of exogenous androgens or 
utilizing a more potent AAS could have more of a significant impact compared to what 
was demonstrated in this study.  
This study was able to show that TBG seems to follow some of the same 
characterization as to what has been reported in humans. There are no significant 
differences in sex, age, or season; however, it would have been expected to see 
significant changes in TBG concentrations throughout gestation in the pregnant mare. It 
is possible that the lack of significance was due to the variation present in the data. This 
aspect deserves further investigation either to reduce the standard error by increasing 
sample size or by looking into possible causes for the lack of TBG increase with 
increasing estrogen concentrations. The lack of significant differences found throughout 
the year would give a good base of measurement to detect significant changes due to 
outside influence. Currently, T3 and T4 concentrations are being analyzed to determine 
whether or not these levels are affected by anabolic steroid administration in the horse.  
 While the possibility of an Equine Biological Passport in equine athletics has been 
proposed, potential biomarkers have not been as extensively studied and characterized as 
in humans. It has been confirmed that SHBG would not be a viable biomarker for AAS 
abuse in the horse, however there is still the possibility that TBG could be utilized. This 
was just the beginning into the characterization of TBG as a potential biomarker in the 
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horse. It is time to start fully investigating other potential biomarkers and pushing toward 
the complete development of the Equine Biological Passport.  
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Appendices: 
Appendix A: Sex hormone-binding globulin purification attempts 
Introduction:  
 As stated in chapter 3, SHBG was not detected in circulation in the horse. The 
following methods and results are what took place during the attempted purification of 
equine SHBG, before RNA sequencing showed the lack of Shbg transcript in the liver. 
While these results further confirm the presence of a carrier protein for androgens in 
circulation in the horse, the lack of Shbg transcript in the liver helps to explain the lack of 
SHBG detection using the following methods. 
Materials and Methods: 
Serum Samples 
Serum from stallions and pregnant mares was used for ultrafiltration, ammonium 
sulfate precipitation, ELISA, affinity chromatography, SDS page, and western blot 
analysis.  
Ultrafiltration 
Amicon Ultra-4 and Ultra-15 filters with a molecular weight cut-off of 10 kDa 
were used and the appropriate volume of sample was concentrated. The ultrafiltration 
centrifuge tubes were centrifuged per manufacturer instruction. The filtrate (fraction that 
passed through the filter) and the concentrate (fraction retained by the filter) were 
collected and stored for later analysis. 
Ammonium Sulfate Precipitation 
A saturated ammonium sulfate solution (SASS) was prepared and used 
throughout the protocol. Various volumes of SASS were added drop-wise to serum at 
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4°C to reach the desired saturation percentage. This solution was then centrifuged at 
10,000xg at 4°C for 10 minutes. The heavy pellet was resuspended and stored for later 
analysis. Additional SASS was added to the supernatant to reach an additional 10% 
saturation. The above centrifugation was repeated and the produced pellet was collected, 
resuspended in buffer, and stored for later use and analysis 
Total Testosterone ELISA  
The ELISA was performed as mentioned in chapter 3. Various samples were 
analyzed: ultrafiltration filtrate and concentrate, ammonium sulfate precipitation pellets 
and supernatants.  
Affinity Chromatography 
DHT-Carboxymethyloxime (CMO)or DHT-Hemisuccinate (Hemi) was bound to 
CarboxyLink agarose resin per manufacturer instruction. Total column volume was 4 
mL. Columns were stored at 4°C and allowed to reach room temperature before any 
experimentation. Serum was added to the column and allowed to incubate for 1 hour at 
room temperature. The columns were then washed with 10 column volumes of buffer. 1 
column volume of DHT in the appropriate buffer was added to the columns which were 
then incubated at 4°C overnight. The following day, 1 column volume of DHT was added 
to the column and the flow-through was collected. The columns were then incubated for 
3 hours at room temperature. This incubation was repeated once more and all flow-
through was collected, pooled, concentrated via ultrafiltration and stored for later analysis 
via SDS page and western blot. Columns were washed with a high salt buffer and stored 
at 4°C for later use.  
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SDS Page 
MiniProtean precast 10% polyacrylamide gels were used for electrophoresis. 
Purified equine albumin was used as a control. Samples were diluted 1:1 using the 
appropriate dye and boiled at 95°C for 5 minutes. The samples were then loaded onto the 
precast gel and run at 200V (constant) for 35-40 minutes. The gels were then placed in 
coomassie blue stain and incubated for 1 hour at room temperature on a plate rocker. 
They were rinsed 3x with ddH2O and then incubated overnight at room temperature in a 
10% acetic acid solution. The following day, gels were again rinsed 3x and preserved in a 
10% glycerol solution.  
Western Blot Analysis 
Following SDS page, the gels were loaded into cassettes with a nitrocellulose 
membrane and run for 1 hour at 100V to allow for protein transfer from gel to the 
membrane. An ice block was placed in the cassettes with a stir bar to prevent overheating 
during the transfer process. The membranes were collected and blocked for 30 minutes at 
room temperature using 5% non-fat dried milk in the appropriate buffer. The membrane 
was rinsed and incubated with the primary antibody (1:100 mouse monoclonal anti-
human SHBG) at 4ºC overnight. The next day the membrane was rinsed 3 times for 10 
minutes each and incubated with the secondary antibody (goat anti-mouse HRP 
conjugated) for 1 hour at room temperature. Finally, the membrane was rinsed and 
incubated for 5 minutes with detection solution before analyzing using a 
chemiluminescent detector.  
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Results and Discussion: 
Ultrafiltration was performed in order to separate testosterone that is bound to 
carrier proteins from testosterone found free in circulation. The filtrate and concentrate 
were analyzed using the total testosterone ELISA to see where the majority of 
testosterone fell. In all samples, most of the testosterone was retained in the concentrate, 
indicating that it is bound to a carrier protein.  
Ammonium sulfate precipitation was performed in order to isolate bound 
testosterone and remove unwanted proteins. This was performed in increment cuts of 
10% saturation. The pellets and supernatants from each 10% cut were analyzed using the 
same total testosterone ELISA. It was found that the majority of testosterone was isolated 
between 45% and 65% ammonium sulfate saturation. These cuts were then run using 
SDS page in order to visualize what and how many proteins were retained. There were 
many proteins on the gel, so these fractions were further purified using affinity 
chromatography.  
Affinity chromatography was also performed on whole stallion and pregnant mare 
serum. The concentrated flow-through was again analyzed using SDS page. These 
samples revealed 3 distinct protein bands. These samples were then analyzed with a 
western blot and the heterologous antibody cross reacted with the equine albumin control. 
Seeing as albumin is the most abundant protein in the body, it is not unusual for there to 
be some albumin contamination during protein purification for antibody production. The 
antibody also cross-reacted with a second unknown band. These samples were sent to the 
UK proteomics core facility for excision and protein sequencing, however SHBG was not 
one of the resulting proteins. 
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Conclusion: 
Results from the total testosterone ELISA following ultrafiltration and ammonium 
sulfate precipitation indicate that there is a carrier protein for sex hormones in circulation 
in the horse. The 3 distinct bands that resulted from running the ammonium sulfate 
fractions through affinity chromatography indicate that there may be 3 proteins in 
circulation that bind to androgens in the horse. Due to the crossreaction of the 
heterologous SHBG antibody with the purified equine albumin control and the presence 
of a protein at the same molecular weight in the affinity chromatography fractions, we 
can confidently conclude that albumin is one of these 3 proteins. As for what the other 2 
proteins may be, the results from the UK proteomics lab generated a list of over 200 
proteins, in addition to albumin. This indicates that the affinity chromatography may not 
have been as specific as initially thought.  
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Figures: 
 
 
Figure A.1: Testosterone following ultrafiltration. Testosterone concentrations were 
obviously higher in the fraction retained by the filter when compared to the fraction of 
serum that passed throught the filter. Data shown is represented at mean ± SEM. Stallion 
and pregnant mare data were combined for the sake of general comparison. 
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Figure A.2: SDS Page and SHBG Western Blot. The SDS page (A) and western blot 
(B) were completed after ammonium sulfate precipitation followed by DHT affinity 
chromatography. Western blot was conducted using a mouse monoclonal anti-human 
SHBG antibody.  
Lane A1 = purified equine albumin, A2 = Stallion serum CMO, A3 = Stallion Hemi, A4 
= Whole Stallion Serum, A5 = Pregnant Mare CMO, A6 = Pregnant Mare Hemi, A7 = 
Whole Pregnant Mare Serum: B1 = purified equine albumin, B2 = Stallion CMO, B3 = 
Pregnant Mare CMO.  
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Appendix B: Thyroxine-binding globulin expression in the horse 
Materials and Methods 
Tissue Collection: 
Livers were collected from three stallions (> 3 years), three pregnant mares (>3 
years), and two fetuses (<10 months gestation). Testes were collected from seven post-
pubertal stallions. Tissues were fixed in RNA later for qPCR and RNA sequencing. All 
tissues were collected post mortem. 
qPCR: 
mRNA was extracted from the collected tissues using the reagent Trizol 
(Invitrogen, Carlsbad, CA, USA). The RNA was then precipitated using 3M sodium 
acetate and isopropanol before being quantitated using NanoDrop (Thermo Fisher 
Scientific; Hampton, NH). Samples with a 230/260 ratio greater than 1.8 and a 260/280 
ratio greater than 2.0 were utilized for further analysis. The DNA-free kit by Applied 
Biosystems was used to DNase treat the RNA. TaqMan Reverse Transcription Reagents 
were used to reverse transcribe RNA to cDNA; 1.25µL MultiScribe Reverse 
Transcriptase, 2.5µL oligo d(T)16 primers, 10µL deoxyNTPs Mixture (2.5mM), 11µL 
25mM MgCl2, 5µL 10x TaqMan RT buffer (Invitrogen). Following the addition of the 
reverse transcription agents, RNA samples were placed in the MasterCycler thermocycler 
(Eppendorf); 10-minute incubation period at 25°C, followed by reverse transcription for 
30 minutes at 48°C and inactivation for 5 minutes at 95°C. SYBR Green Master Mix 
(Applied Biosystems) was used to amplify the resulting cDNA via the ViiA 7 Real-Time 
PCR System (Applied Biosystems, Grand Island, NY, USA) under the following cycle 
conditions: incubation for 10 minutes at 95°C, 45 cycles of 15 seconds at 95°C and 60 
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seconds at 60°C. All of the reactions were performed in duplicate. GAPDH and B2M 
were used as reference genes due to reported stability across the tissue types that were 
analyzed [86-88]. ∆Ct values were analyzed. Primers were generated using Primer Blast 
from the National Center for Biotechnology Information 
(/www.ncbi.nlm.nih.gov/tools/primer-blast/). 
RNA Sequencing: 
Isolation of RNA from testis and liver was performed using RNeasy Mini Kit 
(Qiagen, Gaithersburg, MD, USA) per manufacturer’s instructions. RNA from fetal (n=2) 
and mare (n=2) livers were pooled. Extracted RNA from stallion (n=3) testes were 
pooled. Purity, concentration, and integrity of RNA was analyzed by NanoDrop (Thermo 
Fisher Scientific; Hampton, NH) and Bioanalyzer (Agilent, Santa Clara, CA, USA). All 
samples had a 230/260 ratio greater than 1.8, a 260/280 ratio greater than 2.0 and an 
RNA integrity number greater than 8.0. 
Using TruSeq mRNA Sample Prep kit (Illumina, San Diego, CA USA), library 
preparation was performed as per manufacturer’s instructions. Libraries were then 
quantitated via qPCR and sequenced on a HiSeq 4000, using a HiSeq 4000 sequencing 
kit, version 1 (Illumina), generating 150 bp paired-end reads. Resultant FASTQ files 
were demultiplexed with the bcl2fastq v2.17.1.14 Conversion software (Illumina). 
Sequenced reads were trimmed for adapters and quality using TrimGalore v0.4.4 
(Babraham Bioinformatics; www.bioinformatics.babraham.ac.uk) and quality was 
evaluated via FastQC v0.11.4 (Babraham Bioinformatics). Reads were mapped to 
EquCab2.0 using STAR-2.5.2b (github.com/alexdobin/STAR) using coordinates from 
NCBI. Integrated Genome Viewer v2.3.97 (The Broad Institute; 
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https://data.broadinstitute.org) was used to visually determine the absence or presence or 
reads. 
Results: 
 qPCR was performed in order to characterize the expression of TBG in fetal, 
mare, and stallion livers. Stallion testes were used as a negative control. TBG was 
detected in all liver samples with the highest expression being in the fetal liver. No TBG 
was detected in the testis. These results were further confirmed through RNA sequencing. 
The TBG transcript was seen in all liver samples. No transcript was found in the testes, as 
expected.  
Discussion and Conclusion: 
 These results follow what has been reported for TBG expression in the human and 
other species. While the presence TBG has been detected in other tissues in humans, 
TBG mRNA was only found in the liver. These findings further confirm the presence of 
TBG in the horse, by showing transcript expression in the liver as expected.  
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Figures: 
 
 
Figure B.1: SERPINA7 Expression using qPCR. Bar graph showing SERPINA7 
expression using qPCR. Data shown is delta Ct expressed as mean ± SEM.  
 
 
 
 
 
Figure B.2: SERPINA7 Expression using RNA Sequencing. Expression of SERPINA7 
is shown in pooled mare and fetal liver (A) (FPKM = 251.371) and pooled stallion liver 
(B) (FPKM = 17.3737). This gene shows 4 exons as predicted in the reference sequence 
(C). 
 
 
A 
 
B 
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